MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin MC2-25 ...
(MENAFN- GlobeNewsWire - Nasdaq) MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback